Please assess the completion status of the following clinical trial:

Trial Title: Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented colorectal adenocarcinoma~* Age over 18 years old~* Performance status (ECOG scale): 0-2~* Measurable or evaluable disease~* Patients can take food and drugs orally~* Adequate organ functions~* Life expectancy ≥ 3 months~* Patients should sign a written informed consent before study entry~Exclusion Criteria:~* Tumor type other than adenocarcinoma~* Second primary malignancy~* Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) for advanced or metastatic colorectal cancer~* Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease has been completed within 6 months prior to initiation of study treatment.~* Prior radiotherapy was administered to target lesions selected for this study, or radiotherapy to the non-target lesions has been completed within 4 weeks before randomization.~* Presence of CNS metastasis~* Obvious peritoneal seeding or bowel obstruction disturbing oral intake~* Symptomatic peripheral neuropathy~* Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery. The patient received curative operation or RFA for metastatic disease.~* Serious illness or medical conditions~* Receiving a concomitant treatment with drugs interacting with S-1, capecitabine or oxaliplatin, as follows;flucytosine, a fluorinated pyrimidine antifungal agent phenytoin warfarin etc.~* Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug.~* Pregnant or lactating woman~* Women of child bearing potential not using a contraceptive method~* Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential~* Any patients judged by the investigator to be unfit to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1 and Oxaliplatin (Type: EXPERIMENTAL): S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks
- Capecitabine and Oxaliplatin (Type: ACTIVE_COMPARATOR): Capecitabine and Oxaliplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).